Validation of the severe COVID-19 prognostic value of serum IL-6, IFN-λ3, CCL17, and calprotectin considering the timing of clinical need for prediction.

MLA

Kei Yamamoto, et al. “Validation of the Severe COVID-19 Prognostic Value of Serum IL-6, IFN-Λ3, CCL17, and Calprotectin Considering the Timing of Clinical Need for Prediction.” PLoS ONE, vol. 18, no. 3, Jan. 2023, p. e0279897. EBSCOhost, https://doi.org/10.1371/journal.pone.0279897.

APA

Kei Yamamoto, Yusuke Ohsiro, Tetsuya Suzuki, Michiyo Suzuki, Sayaka Miura, Maki Nagashima, Noriko Iwamoto, Junko S Takeuchi, Moto Kimura, Wataru Sugiura, Satoru Nebuya, Masato Kurokawa, & Norio Ohmagari. (2023). Validation of the severe COVID-19 prognostic value of serum IL-6, IFN-λ3, CCL17, and calprotectin considering the timing of clinical need for prediction. PLoS ONE, 18(3), e0279897. https://doi.org/10.1371/journal.pone.0279897

Chicago

Kei Yamamoto, Yusuke Ohsiro, Tetsuya Suzuki, Michiyo Suzuki, Sayaka Miura, Maki Nagashima, Noriko Iwamoto, et al. 2023. “Validation of the Severe COVID-19 Prognostic Value of Serum IL-6, IFN-Λ3, CCL17, and Calprotectin Considering the Timing of Clinical Need for Prediction.” PLoS ONE 18 (3): e0279897. doi:10.1371/journal.pone.0279897.